GPC3 is a valuable biomarker for HCC, as it is overexpressed in a significant proportion of these tumors while being absent in normal liver tissue and benign liver lesions. Its detection in tissue biopsies aids in the diagnosis and prognosis of HCC. Additionally, GPC3 is a potential therapeutic target; therapies aimed at inhibiting its activity or expression are being explored for HCC treatment.
